Company: KROS
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001664710-25-000046
Chunk: 310

Company: Keros Therapeutics, Inc.
Filing Date: 2025-05-06
Form: 10-Q
Item: Item 2
Chunk 310
---
 Gray, Ran Nussbaum and Alpna Seth, each of whom is 

21

a current member of our board of directors, for election at our 2025 Annual Meeting of Stockholders, or Annual Meeting. In addition, Pontifax has agreed to abide by certain customary standstill restrictions, which remain in effect until the earlier of (x) December 31, 2025 or (y) the thirtieth day prior to the notice deadline under our Amended and Restated Bylaws (as in effect on the date of the Letter Agreement) for the nomination of director candidates by a stockholder for our 2026 Annual Meeting of Stockholders, subject to earlier termination in certain limited circumstances as set forth in the Letter Agreement. We and Pontifax have also agreed to certain non-disparagement obligations.

Known Trends, Events and Uncertainties

While recent trends towards rising inflation have eased, prices continue to rise, which may also materially affect our business and corresponding financial position and cash flows. Inflationary factors, such as increases in the cost of materials and supplies relating to our preclinical studies, clinical trials, interest rates and overhead costs may adversely affect our operating results. Rising interest rates and implementation of tariffs also present a recent challenge impacting the U.S. economy and could make it more difficult for us to obtain traditional financing on acceptable terms, if at all, in the future. Additionally, the general consensus among economists suggests that we should expect a higher recession risk to continue over the next year due in part to ongoing tariff and trade issues, which, together with the foregoing, could result in further economic uncertainty and volatility in the capital markets in the near term, and could negatively affect our operations. Furthermore, such economic conditions have produced downward pressure on share prices. Although we do not believe that inflation, higher interest rates or tariffs have had a material impact on our financial position or results of operations to date, we may experience increases in the near future (especially if inflation rates rise more quickly) on our operating costs, including our labor costs and research and development costs, due to supply chain constraints, consequences associated with public health crises and global geopolitical tensions, such as the ongoing war between Russia and Ukraine and the war in Israel, worsening global macroeconomic conditions, including as a result of bank failures, and employee availability and wage increases, which may result in additional stress on our working capital resources.

Licensing Agreements

2024 License Agreement with Takeda Pharmaceuticals U.S.A., Inc.

In December 2024,